Kornimate/medical-research-clean huggingface dataset:
relationship-based intervention for post-partum depression

Conditions: Post Partum Depression

Summary: a short term dyadic psychotherapy intervention for mothers with post-partum depression and their babies in the first year of life was developed. the investigators believe that following dyadic intervention mothers will show improvement in depressive symptoms, the quality of the mother-child relationship will improve, and maternal and infant's oxytocin levels will rise.

subjects: 60 mothers will be interviewed and diagnosed as suffering from post-partum- depression (ppd) according to the diagnostic and statistical manual of mental disorders, iv version (dsm-iv), enrolling within 3-8 months postpartum. mothers will be recruited through social media networks. additional 40 mothers, 3-8 months postpartum will be assessed and diagnosed as not suffering from ppd or any other psychiatric psychopathology. procedure: the baseline assessment will be conducted at the infant's home. a parent-infant interaction will be videotaped and salivary oxytocin samples will be collected from the infant and from the mother. the women in the ppd group will participate in 8 weeks of dyadic psychotherapy (dp) combining video feedback, or a psycho-educational treatment regarding child development (randomize selection will be made). during the 8-week treatment, salivary oxytocin samples will be collected from the infants and from the mother at the beginning and the end of each session. another assessment will be conducted at the infant's home, at the end of the treatment. as in the baseline condition, this assessment will include videotaped parent-infant interaction, as well as salivary oxytocin samples collection from the mother and from the infant. parent-infant interaction will be filmed and assessed using the cib manual (feldman, 1998) and the synchrony coding system. healthy mothers will undergo the same baseline assessment and a second assessment within 2-3 months, and won't get any treatment.

Eligibility criteria:
inclusion criteria: * women diagnosed with post-partum depression, major or minor, according to the diagnostic and statistical manual of mental disorders, 5th version (dsm-5) * 3-8 months after birth of one baby exclusion criteria: * mothers of twins * mothers of premature babies * comorbidity of psychopathology, women who have severe personality disorder or other psychiatric diagnose, besides depression or anxiety * women or babies who suffer from severe medical condition, such as developmental problems for the baby or disability.

Keywords: post-partum depression dyadic psychotherapy oxytocin
study on antiviral therapy for hbeag-positive chronic hepatitis b patients aged 1-16 years

Conditions: HBeAg Positive Chronic Hepatitis B

Summary: the purpose of this study is to provide theoretical and real world evidence for the optimization of antiviral treatment by ifn combined with nucleosides analog in hbeag positive chronic hepatitis b patients aged 1-16 years，so that the functional cure could be achieved in the greatest extent in pediatric patients

this research is a national multicenter, randomized, prospective study. the planned sample size is 200 subjects in 1-16 years pediatric patients with hbeag positive chronic hepatitis b (chb). these subjects will be randomized (1:1) to group a(treated with nas + ifn for 96 weeks) and group b(treated with nas for 48 weeks, then nas combined with ifn for 96 weeks).meanwhile, 1-6 years and 7-16 years patients should be distributed by 1:1 ratio by random method in both groups. regularly blood cell count, biochemical test, hepatitis b viral markers test, and lymphocyte subsets test were exerted. to compare the curative effect of group a and group b, the primary monitoring indicator is hbsag clearance rate, and the secondary monitoring indicator is hepatitis b virus (hbv) dna clearance，hbeag seroconversion in these patients,. so that we can make the optimal antiviral treatment strategy for 1-16-year-old children with chb，and try to find out the possible influencing factors of function cure

Eligibility criteria:
inclusion criteria: 1. aged 1 to 16 years old. 2. chronic hepatitis b (chb) patients or hbsag positive \> 6 months patients who are line with the diagnostic criteria for chronic hepatitis b infection. 3. alt:40～400 u/l. 4. hbeag positive. 5. hbv dna\>2×104iu/l. 6. liver histology: g\<3. 7. agree to sign the informed consent form (children aged 1-6 years may be signed by the guardian; children between the ages of 7 and 11 are in principle signed by the child and the guardian; those over the age of 12 must be signed by the child and the guardian) exclusion criteria: 1. white blood cell (wbc)\ 34umol/l，alb\ 133umol/l. 2. combined with hav、hcv、hdv、hev or hiv-infected persons. 3. patients combined with other causes of liver disease：alcoholic or non-alcoholic liver disease，thyroid disease，autoimmune liver disease，genetic metabolic liver disease，bile duct diseases，or parasitic infection of hepatobiliary tract. 4. patients with decompensated cirrhosis，including ascites. 5. received the following medications（immunosuppressant and systemic cytotoxic drugs）in six months. 6. patients who are allergy to ifns and nas; 7. patients with other severe or active psychosomatic diseases （kidney, heart, lungs, vascular, neurological, digestive including history of pancreatitis, metabolic diseases including diabetes, thyroid and adrenal disease, adrenal disease or tumor), researchers believe which affect the treatment, evaluation or compliance of patients with the study plan. 8. patients who unable to comply with the study arrangement judged by researcher.

Keywords: hepatitis b,chronic; interferon ; nucleosides;child
vernakalant versus ibutilide in recent-onset atrial fibrillation

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the most common cardiac arrhythmia and is expected to affect about 30 million north americans and europeans by 2050. atrial fibrillation is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. many studies have investigated the efficacy of different drugs in converting atrial fibrillation to sinus rhythm. there are numerous randomized controlled trials that have tested the efficacy of agents against placebo and some trials that directly compared the efficacy of two or more different drugs. the class iii antiarrhythmic drug ibutilde is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset and has been shown to be superior to sotalol and equivalent to flecainide in this indication. recently, the relatively atrial selective antiarrhythmic agent vernakalant has been approved by the european commission for the rapid conversion of recent onset af to sinus rhythm in adults. the investigators hypothesize that the period of time needed for cardioversion to sinus rhythm and the efficacy of cardioversion within 90 minutes is different between vernakalant and ibutilide in patients with recent-onset atrial fibrillation.


Eligibility criteria:
inclusion criteria: * symptoms of atrial fibrillation since no longer than 48 hours * age 18 - 90 years exclusion criteria: * need for immediate electrical cardioversion due to hemodynamic instability (hypotension: systolic blood pressure \< 100 mmhg, dyspnea, loss of consciousness, unstable angina) * moderate to severe heart failure (nyha iii/iv) and patients with previously documented left ventricular ejection fraction (lvef) ≤ 35% * history or signs of acute coronary syndromes (acute myocardial infarction, unstable angina) within the last 30 days * resting ventricular rate \< 80 beats per minute without pace maker back-up * qt interval of \> 440 milliseconds * wolff-parkinson-white (wpw) syndrome * history of torsade de pointes arrhythmias or other polymorphic ventricular tachycardias * signs of thyreotoxicosis * sick sinus syndrome or atrioventricular block greater than first degree * severe valvular heart disease, clinically meaningful hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis * serious disorders of the hepatic, renal (creatinine \> 2.5mg/dl), pulmonary, gastrointestinal, hematologic or central nervous system and serious psychiatric disorders * abnormal serum electrolytes despite adequate therapy (especially potassium \ 5.5 mmol/l) * intravenous use of other class i or iii antiarrythmic drugs within 4 hours of study drug application * pregnancy (a β-hcg test will be performed in all female subjects apart from women \> 50 years and with amenorrhea for at least 12 month (absence of other causes of amenorrhoea) * known hypersensitivity to study medication

Keywords: recent-onset
action observation and motor imagery therapy in stroke

Conditions: Stroke

Summary: in recent years, motor imagery (mi) and action observation (ao) therapy strategies have been used in rehabilitation programs to increase motor learning in stroke. visuomotor training strategies such as ao and mi therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind. this clinical trial aims to test whether the application of ao and mi treatment in stroke in addition to conventional rehabilitation programs has an additional effect on motor recovery, activities of daily living, and quality of life.

stroke is one of the most common neurological disorders that causes chronic disability in adulthood. stroke-related neurological dysfunction causes impairment in motor and sensory skills and limitation in the ability to perform daily living activities, resulting in decreased independence of patients. this process causes significant impairment in the quality of life of stroke patients. in recent years, motor imagery (mi) and action observation (ao) therapy strategies have been used in rehabilitation programs to increase motor learning in stroke. visuomotor training strategies such as ao and mi therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind. this clinical trial aims to test whether the application of ao and mi treatment in stroke in addition to conventional rehabilitation programs has an additional effect on motor recovery, activities of daily living, and quality of life.

Eligibility criteria:
inclusion criteria: * patients who had a stroke in the last year * functional ambulation classification score 2-5 exclusion criteria: * patients who have had repeated strokes * patients with neglect * patients with cognitive dysfunction (those who cannot follow simple verbal instructions) * patients with severe hearing problems * patients with severe vision problems * patients with additional musculoskeletal system pathology that will affect physical performance (such as amputation, severe joint mobility limitation, peripheral nerve damage) * patients with uncontrolled hypertension and diabetes mellitus * patients with a history of symptomatic lung disease (such as asthma, chronic obstructive pulmonary disease, emphysema) * patients with a history of symptomatic cardiac disease (such as coronary artery disease, arrhythmia, heart failure) * patients with peripheral artery disease
cefaly® device in the treatment of patients with fibromyalgia.

Conditions: Fibromyalgia

Summary: the objective of this pilot open trial was to assess the efficacy and safety of external trigeminal nerve stimulation (e-tns) with the cefaly® device in fibromyalgia.

the main objective of this clinical pilot trial was to evaluate the use of external trigeminal nerve stimulation (e-tns) with the cefaly® neurostimulator device as a new therapeutic treatment for fibromyalgia.

Eligibility criteria:
inclusion criteria: 1. aged from18 to 65 years (on the day of signing the informed consent form). 2. diagnosed with fibromyalgia according to the 2010 american college of rheumatology preliminary diagnostic criteria for fibromyalgia (acr 2010). 3. having a minimum pain score of at least 4 on the 0-10 fibromyalgia impact questionnaire-revised (fiqr) pain scale at screening and baseline. exclusion criteria: 1. women: pregnant, lactating or \<6 months post partum. 2. episodic or chronic migraine according to the diagnostic criteria listed in international classification of headache disorders (ichd)-3 beta (2013) section 1, migraine 1, having two or more attacks per month. 3. change in any medication acting on the central nervous system (cns) within 28 days before start of the study or during the study. 4. severe depression i.e. having a beck depression inventory-fast screen (bdi-fs) score \>12. 5. botox injection within 4 months before baseline or during the study. 6. psychiatric disorders that could interfere with study participation: bipolar disorder, psychotic disorders and dementia. 7. suicidal behavior and/or ideation i.e. having a columbia suicide severity rating scale (c-ssrs) score ≥ 4 during the preceding 2 years. 8. patients currently taking any opioid medication. 9. patients currently taking medically prescribed marijuana. 10. current or history during the preceding year of alcohol or substance abuse including marijuana. 11. widespread rheumatic diseases (other than fibromyalgia), evidence of inflammatory rheumatic disease. 12. any unstable medical condition in the judgment of the investigator that would interfere with study participation or study assessments. 13. implanted active metal or electrical devices in the head. 14. cardiac pacemaker or implanted or wearable defibrillator. 15. intolerance to supraorbital neurostimulation that makes the treatment not applicable (test of nociceptive threshold with specific cefaly program).
incidence of hypertrophic cardiomyopathy in infants of diabetic mothers attending in nicu at assiut university children hospital during one year

Conditions: Hypertrophic Cardiomyopathy

Summary: to evaluate all full term infants of diabetic mother for the presence of hypertrophic cardiomyopathy who admitted in nicu at assiut university children hospital and to follow up of these cases after 6 months for recovery.

diabetes is the most common endocrine disorder complicating pregnancy. incidence of both type-i and type-ii diabetes is increasing, throughout the world. as the incidence of diabetes continues to rise and increasingly affects individuals of all ages including young adults and children, women in child bearing age are at increased risk of diabetes during pregnancy \[1\]. the type 1 diabetes around the time of conception produces marked risk of embryopathy (neural tube defects, cardiac defects, and caudal regression syndrome) as these mother have high glycosylated hemoglobin at the time of embryogenesis (around 6-8 weeks of gestation) rather than idm that are born to type 2 diabetes mothers who have macrosomia and other milder problems. the mothers who have been diagnosed as severe and unstable type1 diabetes in the later part of gestation have high chances of neonate being more affected with intrauterine growth restriction, asphyxia, and fetal death \[2\] and \[3\]. due to the teratogenic effect of maternal diabetes, the reported incidence of congenital malformations among the newborns of diabetic mothers is five times greater than that of the general population \[4\]. cardiac malformations are one of the most common types of these malformations which occur in about 8.5% of cases that is about 10 times more than its incidence in normal population (0.8%) \[5\]. fetuses exposed to maternal hyperglycemia and hyperinsulinism, are prone to develop hypertrophic cardiomyopathy. it primarily affects the inter-ventricular septum, but can extend to the myocardium in more severe cases. although the perinatal mortality rates associated with diabetes in pregnancy have declined considerably during the past eight decades and are now near those in the general population, it is only through continuing vigilance that such advances can be maintained. both fetal and neonatal deaths occurred with increased frequency in diabetic pregnancies before the advent of modern management methods, and fetal deaths nationwide continue to be significantly higher among diabetic than non-diabetic pregnancies \[6\]. the most recent available data indicate that the relative risk of stillbirth in pregnancies complicated by type 1 diabetes (compared to the general population) is 2.9-4.3 folds, and for type 2 diabetes 2.5-4.5 fold \[7\].

Eligibility criteria:
inclusion criteria: * all infants of diabetic mothers were admitted at nicu exclusion criteria: * no
curing atrial fibrillation in heart failure

Conditions: Chronic Heart Failure; Atrial Fibrillation

Summary: heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. half of these patients have an irregularity of heart rhythm called atrial fibrillation (af). patients with both heart failure and af spend more time in hospital, and die earlier than those with heart failure alone. af is difficult to treat with conventional methods in patients with heart failure. radiofrequency ablation is a new technique used to cure af. the investigators aim to establish if radiofrequency ablation for atrial fibrillation in patients with advanced heart failure can result in marked improvement in the function of the heart.


Eligibility criteria:
inclusion criteria: * informed consent * persistent atrial fibrillation (af) * new york heart association (nyha) ii, iii and iv chronic heart failure (chf) despite optimal medical therapy for at least 3 months * left ventricular ejection fraction (lvef) \<35% - as measured by radionuclide ventriculography (rnvg) * patients with chf secondary to ischaemic and non-ischaemic aetiology exclusion criteria: * qrs duration \>150ms (or qrs 120-150 with evidence of mechanical cardiac dysynchrony) * magnetic resonance imaging (mri) - incompatible metallic (ferrous) prosthesis * primary valvular disease as a cause of chf * reversible causes of chf * acute myocarditis * patients aged 18 or less * patients having undergone revascularisation procedures within 6 months * paroxysmal af * pregnancy * expected cardiac transplantation within 6 months

Keywords: chronic heart failure atrial fibrillation radiofrequency ablation
prophylactic implantation of biologic mesh in peritonitis (prophybiom)

Conditions: Incisional Hernia

Summary: to evaluate the efficacy of the use of swine dermal collagen prosthesis implanted preperitoneally as a prophylactic procedure against incisional hernia in patients operated in urgency/emergency setting in contaminated/infected fields with peritonitis. the aim of the study is to reduce the incidence of incisional hernia from 50% to 20%.


Eligibility criteria:
inclusion criteria: * • patients aged \> 18 years old * clinical and/or laboratory and/or radiological evidence/signs of peritonitis of any origin (peritoneal reactivity, positive blumberg sign, fever, free air/fluid in abdominal cavity, leucocytosis, increased crp (c-reactive protein, lactic dehydrogenase (ldh), tachycardia, tachypnea, clinical or radiological evidence/suspect of bowel ischemia) * eventual strong suspect of possible bacterial translocation (reduction of the natural intestinal barrier against bacterial translocation, i.e. bowel ischemia, bowel overdistension, intestinal occlusion, etc.) * surgical indication for midline laparotomy independently from eventual previous laparotomies * informed consent exclusion criteria: * • patients aged \< 18 years old * informed consent refusal * no clinical and/or laboratory and/or radiological evidence/signs of peritonitis of any origin. * surgical indication for laparotomies other than midline one * pregnancy

Keywords: peritonitis patients
is wgrs associated with dd recurrence?

Conditions: Dupuytren Contracture

Summary: rationale: retrospectively reviewing the participants of the goddaf database, revealed a significant association between the weighted genetic risk score and dupuytren disease recurrence. however, a significant dose-response relation was not found. this might be caused by underestimating the recurrence rate, due to the retrospective nature of determining recurrence. therefore, we want to do a follow-up measurement of the goddaf participants, to see whether they suffered from recurrent disease. objective: we aim to determine whether the wgrs is associated with recurrent dd. study design: an observational study, in which the participants of the goddaf study are followed up. study population: patients affected by dupuytren disease, aged 18-96 years, who were previously included in another study on the genetic basis of dupuytren disease. intervention (if applicable): na main study parameters/endpoints: the main study parameter is the presence of recurrent dupuytren disease.


Eligibility criteria:
inclusion criteria: * dd patient * participant in the goddaf study * genetic data passed the quality control * surgical treatment of dd * written informed consent exclusion criteria: * decisionally incapacitated * patients treated for dd with collagenase or radiotherapy
the effectiveness of visual training in convergence insufficiency patients

Conditions: Convergence Insufficiency

Summary: convergence insufficiency (ci) is one of the most common binocular vision disorders. the prevalence of ci ranges from 3% to 6% in school-aged children. ci symptoms include visual fatigue, headache, blurred vision, and diplopia and could be caused while using near-distance viewing. these symptoms might become more severe with increasing need to perform near-distance tasks. long-term visual symptoms could result in a negative impact on learning behaviors and work performance in patients. nowadays, visual training is the main type of management for ci patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. therefore, this study will use a simple training method by utilizing prisms for ci patients to train at home, then compare visual symptoms and binocular vision after the training. in stage i of this study, investigators will recruit 60 symptomatic ci participants aged 9 to 30 years old to do a 6-week visual training with the prisms (15 min/time, 3 times/week). the post-training outcomes will be collected at week 4 and week 6. in stage ii, all of the participants will be randomly divided into the "stop training group" and the "continue training group." the participants in the "continue training group" will have the same 6-week prism training and in the "stop training group" will stop all the prism training during this period. the final post-training outcomes of all the participants will be collected again at week 12. in this study, investigators will investigate the effectiveness of the prisms training for 6 weeks and for 12 weeks on visual symptoms and binocular vision in ci patients, and evaluate whether the training effect will be affected by stopping training after 6 weeks.


Eligibility criteria:
inclusion criteria: 1. the overall score of ci symptom survey ≥ 16 (9-18 years old) or ≥ 21 (19-30 years old) 2. the break point of near point of convergence (npc) ≥ 6 cm 3. exophoria at near distances be at least 4∆ higher than at far distances 4. near positive fusional vergence (pfv) ≤ 15∆ or failing sheard's criterion at near. exclusion criteria: 1. the best corrected visual acuity (bcva) of \< 20/25 in each eye at far and near distances 2. amblyopia patients or the difference of bcva between the two eyes ≥ 2 lines 3. constant strabismus patients 4. history of strabismus surgery or refractive surgery 5. systemic diseases that would affect binocular vision 6. acquired brain injury or neurological disorder.

Keywords: visual training prism binocular vision